Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somaxon To Conduct Preclinical Tests On Its Phase III Insomnia Drug Silenor

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has requested that preclinical studies on low-dose doxepin be included in the 505(b)(2) application.

You may also be interested in...



Silenor’s Bleary Regulatory Timeline May Clear Up

Somaxon’s sleep aid is on track for a third-quarter NDA submission; partnering deal also expected during 2007.

Silenor’s Bleary Regulatory Timeline May Clear Up

Somaxon’s sleep aid is on track for a third-quarter NDA submission; partnering deal also expected during 2007.

Somaxon To Put Silenor Phase III Program To Bed In December

Firm's Q3 2007 filing timeframe puts it ahead of Neurocrine's resubmission plans for immediate-release indiplon.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel